Introduction
The Ca V 2 subfamily of voltage-dependent calcium channels serves a critical role in the nervous system. This subfamily consists of Ca V 2.1 (P/Q-type), Ca V 2.2 (N-type) and Ca V 2.3 (R-type) channels. T hese calcium channels provide the main pathway for voltage-triggered calcium influx and subsequent neurotransmitter release at many synapses. Although all three subfamily members likely contribute to processing nociceptive inputs (Pietrobon, 2005) , most drug discovery efforts seeking treatments for pathological pain have focused on the Ca V 2.2 subtype (Yamamoto and Takahara, 2009 ).
There is extensive evidence to support Ca V 2.2 as a target for chronic pain treatment. Ca V 2.2 channels are highly expressed in laminae I and II of the spinal cord (Gohil et al., 1994; Westenbroek et al., 1998) and are up-regulated in behavioral pain models (Abbadie et al., 2010; Cizkova et al., 2002) . Laminae I and II serve as critical relay points in the transmission of pain information into the CNS, where primary nociceptors make synaptic connections with dorsal horn neurons of the spinal cord.
Opening of p resynaptic Ca V 2.2 channels in r esponse to depolarization of the primary afferent terminal triggers release of transmitter into the synaptic cleft (Evans et al., 1996) . Blocking these Ca V 2.2 channels with conopeptides attenuates nociception in behavioral models of neuropathic and inflammatory pain (Malmberg and Yaksh, 1995; Scott et al., 2002) . Furthermore, Ca V 2.2 knockout mice display reduced pain sensitivity in a number of pain models (Abbadie et al., 2010; Hatakeyama et al., 2001; Kim et al., 2001; Saegusa et al., 2001) . Perhaps most convincing are the clinical data from ziconotide, a selective peptide blocker of Ca V 2.2 channels, which is efficacious in the treatment of chronic pain (Miljanich, 2004) .
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small therapeutic window and intrathecal route of administration (Miljanich, 2004; Staats et al., 2004) . A lthough some state-dependence to ziconotide block is revealed at very negative potentials, within physiological voltage ranges ziconotide potently inhibits Ca V 2.2 channels regardless of whether they are in the open, closed, or inactivated state (Feng et al., 2003; Stocker et al., 1997) . Small molecule inhibitors demonstrating strong state-dependent inhibition have been well described for L-type and T -type calcium channels (e.g. (Bean, 1984; McDonough and Bean, 1998) and it has been proposed that a state-dependent Ca V 2.2 inhibitor, which preferentially binds to channels in open or inactivated states, may provide efficacy with an improved therapeutic window over ziconotide due to enhanced activation of Ca V 2.2 channels in pain conditions (McGivern and McDonough, 2004; Snutch, 2005; Winquist et al., 2005) . A number of small molecule Ca V 2.2 inhibitors have been described in the literature (reviewed in Yamamoto and Takahara, 2009) , although detailed mechanistic characterizations of these compounds have not been reported, preventing determination of the value of state-dependent inhibitors in pain treatment.
TROX-1, a s ubstituted N-triazole oxindole, is a Ca V 2.2 inhibitor which exhibits efficacy in a number of animal pain models with a therapeutic window for both cardiovascular and CNS side effects (Abbadie et al., 2010) . H ere we show electrophysiologically that TROX-1 inhibits Ca V 2.2 channels in both a state-dependent and use-dependent manner. Since state-dependent calcium channel inhibitors can exhibit apparent subtype selectivity due to different levels of channel inactivation across channel subtypes, we measured the activity of TROX-1 on members of the Ca V 2 subfamily at 
Cell lines and growth conditions
Stable HEK293 cell lines expressing human Ca V 2 calcium channels were previously described (Dai et al., 2008) . The Ca V 2.1 stable line expressed the α 1A-2 (P-type) splice variant (Hans et al., 1999) . The Ca V 2.2 cell lines (2H8 and CBK) utilized the long form of α 1B-1 (Williams et al., 1992) . For Ca V 2.3, the α 1E-3 splice variant was used (Williams et al., 1994) . Each cell line expressed α 2bδ-1 and β 3a auxiliary subunits (Williams et al., 1992) . F ollowing creation of th e stable cell lines expressing calcium channels, each line was transfected with cDNA encoding human Kir2.3 (KCNJ4) (Perier et al., 1994) substantial rundown and that the currents were sufficiently recovered from the previous prepulse. Re sulting data were fit to a Bo ltzmann function:
where y is the current normalized with respect to the maximal current, V h is the voltage at which half activation or inactivation is reached, V is the voltage, and k is the slope factor.
Data are reported as the mean ± S.E.M.
Automated Electrophysiology using PatchXpress
PatchXpress™ is a 16-well whole-cell automated patch clamp device that operates asynchronously with fully integrated fluidics (Molecular Devices Corp, Sunnyvale, CA).
For PatchXpress™ experiments, cells were grown in T75 culture flasks and dissociated with trypsin 30-60 minutes before use. Capacitance and series resistance compensation were automatically applied and no correction for liquid junction potentials was employed.
Leak subtraction was performed using the P/N procedure. V oltage protocols and t he recording of me mbrane currents were performed using the PatchXpress™ software/hardware system and current amplitudes were calculated with DataXpress™ software. In order to increase current amplitudes and assay reliability, the same 20 mM barium external solution and corresponding internal solution used for t he manual with the slope fixed to 1.
Ca V 2.x Channel Calcium Influx Assays
Fluorescence-based calcium influx assays as described in Dai et al. (2008) were used to characterize the effects of TROX-1 on Ca V 2.x channels. Expression of Kir2.3 channels in each cell line allowed control of cell membrane potential through changes in bath potassium concentration (Dai et al., 2008) . This article has not been copyedited and formatted. The final version may differ from this version. 
Results

Characterization of Ca V 2.2 cell lines
The Ca V 2.2 (2H8) cell line used in the calcium influx assay and the Ca V 2.1 and Ca V 2.3 cell lines used in both the electrophysiological and influx assays were previously characterized (Dai et al., 2008) . For electrophysiological studies involving Ca V 2.2, a new cell line was created with improved current stability. New cell lines were created using a dual vector approach (see Materials and Methods). Clones with high Ca V 2.2 expression were initially selected using an 125 I-ω-CgTx-GVIA binding assay and then characterized electrophysiologically on the PatchXpress™, an automated patch clamp platform, to select clones with high functional expression, appropriate biophysical properties, and favorable current stability over time. U sing these criteria, the bMHN-4 clone was selected for electrophysiological experiments. The current expressed in the bMHN-4 cell line was larger than that in the original CBK line and, although smaller than that expressed in the 2H8 cell line, was more stable over time (Table 1 , Fig. 1A ). T he bMHN-4 cell line was characterized in more detail by conventional electrophysiology.
Maximal current was elicited at ~ +5 mV with half activation occurring at +4 mV and half inactivation at -80 mV (Fig. 1B) . A ddition of 500 nM of the Ca V 2.2-selective peptide inhibitor, ω-conotoxin-GVIA, inhibited 99% of the current elicited from voltage steps to +10 mV (n=3 cells; Fig. 1C ).
TROX-1 inhibits Ca V 2.2 currents in a voltage-and use-dependent manner
State-dependent inhibition of Ca V 2.2 channels by TROX-1 was evaluated by applying the compound at two different membrane potentials using the bMHN-4 recombinant cell line.
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 2B ) and the hyperpolarized (Fig. 2C ) assay formats.
Using the depolarized protocol, TROX-1 inhibited Ca V 2.2 in a concentration-dependent manner with an estimated IC 50 of 0.11 μM (Fig. 2D) . Under hyperpolarized conditions, where channels are biased towards the closed state, TROX-1 was less potent, blocking only 14 ± 6% and 45 ± 7 % of the calcium current at 0.3 μM and 3 μM, respectively .
The dependence of TROX-1 activity on membrane potential and channel state was further characterized using PatchXpress™. As for the manual patch clamp assay, cells were stepped to +10 mV every 15 seconds to elicit current and evaluate inhibition. The holding potential, however, was varied in 20 mV increments from -110 mV to -70 mV for different groups of cells. Representative current versus time plots and current traces are shown for TROX-1 inhibition of Ca V 2.2 from a holding potential of -70 mV (Fig. 3A) and -110 mV (F ig. 3B). Similar to the results for ma nual patch assay, the apparent This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 3C ).
Use-dependent inhibition of Ca V 2.2 channels expressed in t he CBK cell line was examined using PatchXpress™. The CBK cell line was chosen because the currents in response to voltage trains were more stable than the currents in 2H8 or bMHN-14 cells.
The cause of these stability differences is unclear but may involve differences in channel inactivation across the cell lines. The Ca V 2.2 currents in CBK cells exhibit a more depolarized, two component steady-state inactivation curve probably due to limiting expression of β3a (discussed in Dai et al., 2008) . CBK cells were voltage clamped at -60 mV, which corresponds to ~80% availability at steady-state, and trains of 20 pulses (25 ms) to +20 mV were applied at a frequency of 2 H z every 5 m inutes. Representative currents at pulse 1 and p ulse 20 under control conditions and in the presence of 3 μM TROX-1 are shown in Fig. 4A . Inspection of the time course of current reduction during the pulse train shows that i nhibition mainly develops over the first 10 pulses and has reached steady-state by the 20 th pulse (Fig. 4C) . The averaged data presented in Fig. 4B illustrates that TROX-1 inhibited the current elicited at pulse 20 more potently (IC 50 = 2.4
μM) than the current elicited at pulse 1 (IC 50 = 24 μM) indicating enhanced inhibition of Ca V 2.2 channels after a tr ain of depolarizing pulses that open and inactivate Ca V 2.2 channels.
Together, these data demonstrate TROX-1 inhibits Ca V 2.2 channels in both a voltage-and use-dependent manner and are consistent with state-dependent inhibition of inactivated and/or open channels by TROX-1.
This article has not been copyedited and formatted. The final version may differ from this version. 
TROX-1 inhibits other members of the Ca V 2 subfamily of calcium channels
In manual electrophysiology experiments TROX-1 activity was compared across other members of the Ca V 2 subfamily of calcium channels to assess its selectivity profile.
Lower expression levels in the Ca V 2.1 and Ca V 2.3 cell lines required an increase in the concentration of th e barium charge carrier from 5 mM (Fig. 2) to 20 mM. T ROX-1 activity on Ca V 2.2 was re-assessed using 20 mM barium as the charge carrier to allow for a direct comparison of potency across all three Ca V 2 subfamily members without concern for potency shifts that might result from differences in the concentration of the charge carrier. TROX-1 inhibition of Ca V 2 currents was measured using both 'hyperpolarized'
and 'depolarized' voltage formats as described previously (Dai et al., 2008 This article has not been copyedited and formatted. The final version may differ from this version. TROX-1 inhibition of Ca V 2 channels was also examined in a calcium influx assay on a FLIPR™ with the throughput to assess inhibition of all three subfamily members across a range of conditions (see Dai et al., 2008) . T his assay utilizes Ca V 2.1, Ca V 2.2 and (Dai et al., 2008) , the fluorescence values from Fig. 6 show that the calcium This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. (μM) conditions (Abbadie et al., 2010) . The state-dependence of T ROX-1 inhibition of calcium channels was also observed using a calcium influx assay where the TROX-1 IC 50
shifted from 0.69 μM under high external potassium (14 mM K + , partially inactivated) conditions to 9.48 μM under low external potassium (4 mM K + ) conditions. This is in reasonable agreement with the 0.27 μM and >10 μM values from Abbadie et al. (2010) which were obtained using a di fferent cell line and with 30 mM K + for t he high potassium condition. Electrophysiologically, TROX-1 also inhibited Ca V 2.2 channels in a use-dependent manner. TROX-1 inhibited Ca V 2.2 current during the 20 th pulse of a 2
Hz train approximately 10-fold more potently then during the 1 st pulse of the train. hyperpolarized from the foot of the inactivation curve for Ca V 2.1 (see Fig 1B and Dai et al. (2008) Fig. 2D) . Th e apparent difference in potency, therefore, may reflect the fact that the Ca V 2.1 potency at -100 mV better approximates closed-state inhibition. The results from t he calcium influx experiments support this interpretation. In the calcium influx assays, the relationship between IC 50 and external potassium is shifted to higher potassium concentrations (more depolarized) for Ca V 2.1 relative to Ca V 2.2 and Ca V 2.3
( Fig. 7A-C) . If, however, IC 50 values are plotted versus fractional reduction in calcium signal to normalize for channel inactivation, TROX-1 potency is essentially identical for Ca V 2.1, Ca V 2.2 and Ca V 2.3 across a range of inactivation levels (Fig. 7D) . These results suggest that TROX-1 is interacting with the inactivated state of the channel, although these data do not exclude other potential mechanisms such as effects on open channels, channel activation, or closed-closed channel state transitions the might occur at depolarized potentials. While these results indicate that there may be little true molecular selectivity within the Ca V 2 subfamily, TROX-1 could still be functionally selective against less inactivated Ca V 2 calcium channels. This is likely a physiologically relevant consideration as Ca V 2 inactivation levels are not only modulated by the voltage and activity of the neurons expressing them, but also can be dependent on the splice variant (Bourinet et al., 1999; Thaler et al., 2004) , co-expressed auxiliary subunit (De Waard and Campbell, 1995) , or interacting proteins including synaptic proteins (Bezprozvanny et al., 1995; Kiyonaka et al., 2007; Zhong et al., 1999) This article has not been copyedited and formatted. The final version may differ from this version. Molecular selectivity can be examined in both the electrophysiological and calcium influx assays by measuring potency under similar levels of inactivation (see also Dai et al., 2008) , however, more caution should be taken when comparing the absolute degree of state-dependence across the different Ca V 2 assays. The degree of statedependence is determined by comparing the potency under depolarized conditions to the potency under hyperpolarized conditions where channels are presumed to be largely in the closed-state. However, as discussed above for t he electrophysiological assay, the potency values in the calcium influx assay under hyperpolarized conditions (low potassium) are likely influenced by the proximity of the cell resting potential to the foot of the inactivation curve. Ca V 2.1 and Ca V 2.2 channels appear largely non-inactivated at 4 mM extracellular K + in these cell lines since the top of the inactivation curves are relatively flat (Figs. 7A,B) . The decreasing signal for Ca V 2.3, however, suggests that it is close to the foot of its inactivation curve and this may contribute to its slightly increased potency in 4 mM K + (Fig. 7C ) and, therefore, its reduced apparent state-dependence. As a result, the state-dependent measures from these assays are most useful for comparing different compounds on the same channel rather than the same compound across different channels.
There is a tendency for TROX-1 to appear more potent in the electrophysiological assays. This is consistent with that reported for two other Ca V 2.2 inhibitors assessed in these same assays (Dai et al., 2008) and m ay be tied to differences between the assay formats. While the cell membrane potentials in the calcium influx assay are likely to be relatively constant during compound incubation, the cells are depolarized periodically in The issue of selectivity within the Ca V 2 subfamily of calcium channels raises the question-how might the individual inhibitory activities on Ca V 2.1, Ca V 2.2, and Ca V 2.3 influence overall efficacy and safety profiles? Genetic ablation of these channels in mice likely only provides a partial answer. Ca V 2.3 -/-mice, for example, have been reported to be resistant to inflammatory pain but otherwise exhibit a predominantly normal phenotype with alterations in glucose metabolism Saegusa et al., 2000; Wilson et al., 2000) . Reports on the role of Ca V 2.1 channels in pain have been less straightforward with evidence of reduced pain sensitivity in t he Ca V 2.1 knockout mice (Luvisetto et al., 2006) but hypersensitivity using pharmacological blockade of Ca V 2.1 at supraspinal levels (Ebersberger et al., 2004; Knight et al., 2002) . In terms of potential adverse effects, Ca V 2.1 -/-mice, which die within 3-4 weeks of birth, exhibit ataxia, dystonia, and absence seizures. This phenotype is consistent with human Ca V 2.1 loss-offunction mutations which result in episodic ataxia and absence seizures (Pietrobon, 2005) . Despite this, the efficacy and safety data of TR OX-1 in animal models suggest that an adequate safety window can be obtained with a state-dependent, non-selective Ca V 2 inhibitor (Abbadie et al., 2010) . The therapeutic window for a given compound is likely to depend on both its molecular selectivity as well as its degree of statedependence. Until additional studies are reported for a r ange of Ca V 2.2 inhibitors, the combination of selectivity and state-dependent profiles that best maximize the safety window will remain an open question.
This article has not been copyedited and formatted. The final version may differ from this version. various potencies and selectivity profiles (Yamamoto and Takahara, 2009 (Abbadie et al., 2010; Zamponi et al., 2009; Zhang et a l., 2008) . Selectivity against Ca V 3 (T-type) calcium channels and other Ca V 2 subfamily members has also been reported but, in general, have been much more limited (Yamamoto and Takahara, 2009) . A s shown here, for state-dependent inhibitors, it is important to generate selectivity data in assays producing similar degrees of channel inactivation. Furthermore, a more informative and detailed understanding of inhibitor selectivity profiles can be obtained by looking at potencies across a range of volt ages and inactivation levels, particularly for closely related family members where true molecular selectivity may be more difficult to obtain. This is illustrated in the electrophysiological selectivity data for Ca V 2.1, Ca V 2.2 and Ca V 2.3 at -100 mV where TROX-1 appears to be ~30-fold selective over Ca V 2.1 channels but, actually, shows no true molecular selectivity.
TROX-1 is a n orally available, small molecule Ca V 2.2 inhibitor with efficacy in a number of animal models and a demonstrated therapeutic window in animals over cardiovascular and neurological side effects (Abbadie et al., 2010) . This paper provides a detailed characterization of the state-dependent and use-dependent properties of TROX-1.
The comprehensive selectivity characterization shows that TROX-1 is a state-dependent inhibitor of all members of the Ca V 2 subfamily with similar potency when normalized to the degree of inactivation. Together, these data support the idea that a state-dependent Ca V 2 inhibitor can provide an improved therapeutic window over a r elatively stateThis article has not been copyedited and formatted. The final version may differ from this version. independent Ca V 2.2 inhibitor, such as ziconotide (Abbadie et al., 2010; Snutch, 2005 values vs the fractional reduction in the peak calcium signal for Ca V 2.1 (blue), Ca V 2.2 (red) and Ca V 2.3 (green).
